Literature DB >> 22001294

Differential role of cyclooxygenase isozymes on neuronal density in hippocampus CA1 region of intracerebroventricular streptozotocin treated rat brain.

Dinesh K Dhull1, Deepak Bhateja, Rakesh K Dhull, Satyanarayana S V Padi.   

Abstract

Intracerebroventricular (ICV) administration of streptozotocin (STZ) causes degeneration of hippocampal neurons through unknown mechanisms that further lead to dementia. On assumption that enzyme cyclooxygenase (COX), which catalyzes the production of pro-inflammatory prostaglandins, may be involved in ICV-STZ induced neurodegeneration, the present study was designed to investigate the effects of chronic treatment with selective inhibitor of COX-1, COX-2 or COX-3 on hippocampal neuronal density in ICV-STZ treated rats. Drugs were administered daily for 21 days, intraperitoneally, in sham control as well as ICV-STZ treated rats. After 21 days of treatment, rats were sacrificed and histological changes were observed in Cornus Ammonis (CA)-1 region of hippocampus at light microscopic level. Histopathological evaluation showed that valeryl salicylate (selective COX-1 inhibitor; 5 and 10 mg/kg; i.p.) and etoricoxib (selective COX-2 inhibitor; 5 and 10 mg/kg; i.p.) significantly increased the survival of hippocampus CA1 neurons in a dose dependent manner. On the contrary, phenacetin (selective COX-3 inhibitor; 20 and 40 mg/kg; i.p.) treatment had no effect on reduced neuronal density in ICV-STZ treated rats. In summary, these findings provide the first comprehensive description about the differential role of COX isozymes in ICV-STZ induced neuronal death in hippocampal CA1 regions of the rat brain.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001294     DOI: 10.1016/j.jchemneu.2011.10.001

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  5 in total

1.  Hypobaric Hypoxia Induces Deficits in Adult Neurogenesis and Social Interaction via Cyclooxygenase-1/ EP1 Receptor Pathway Activating NLRP3 Inflammasome.

Authors:  Garima Chauhan; Gaurav Kumar; Koustav Roy; Punita Kumari; Bhanuteja Thondala; Krishna Kishore; Usha Panjwani; Koushik Ray
Journal:  Mol Neurobiol       Date:  2022-01-28       Impact factor: 5.590

Review 2.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

Review 3.  What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research.

Authors:  Melita Salkovic-Petrisic; Ana Knezovic; Siegfried Hoyer; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-08-12       Impact factor: 3.575

4.  Tramadol ameliorates behavioural, biochemical, mitochondrial and histological alterations in ICV-STZ-induced sporadic dementia of Alzheimer's type in rats.

Authors:  Dinesh K Dhull; Anil Kumar
Journal:  Inflammopharmacology       Date:  2017-12-16       Impact factor: 4.473

5.  PTGS-2-PTGER2/4 signaling pathway partially protects from diabetogenic toxicity of streptozotocin in mice.

Authors:  Antje Vennemann; Anemone Gerstner; Niklas Kern; Nerea Ferreiros Bouzas; Shuh Narumiya; Takayuki Maruyama; Rolf M Nüsing
Journal:  Diabetes       Date:  2012-04-20       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.